FDA Brief

Warning letters Drugs

FDA warning letter to

Eurofins SF Analytical Laboratories, Inc.

High riskIssued Oct 6Posted Oct 13Center for Drug Evaluation and Research (CDER)

FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

What happened

FDA inspected the firm's contract testing laboratory at 215 Witmer Road, Horsham, Pennsylvania, from June 1 to 3, 2026. Investigators found that microbiologists did not record results that were too numerous to count, recorded counts from cracked and dried-out plates as within limits, and recorded 0 colonies on a plate where an investigator saw a colony. FDA called the firm's June 22, 2026 response inadequate.

What FDA found

  1. Laboratory records did not include complete test data: analysts left out results that were too numerous to count and relied on damaged plates, so the counts could not be trusted.

    21 CFR 211.194(a)
  2. The firm did not thoroughly investigate cracked or dried-out test plates used for raw material and drug product samples.

    21 CFR 211.192
  3. The quality unit did not have or use enough authority and oversight to keep laboratory operations in line with CGMP.

    21 CFR 211.22

What FDA wants

FDA tells the firm to send a written response within 15 business days that includes independent assessments of its laboratory and investigation systems, detailed corrective and preventive action plans, and a plan to strengthen the quality unit. FDA also recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • drug manufacturers that send samples to this contract testing laboratory
  • quality teams that rely on outside lab certificates of analysis for batch release
  • companies using contract microbiology labs for raw material and finished product testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk